

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣州藥業股份有限公司

Guangzhou Pharmaceutical Company Limited

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 0874)

UNUSUAL FLUCTUATIONS IN TRADING OF A SHARES

1. THE FLUCTUATIONS IN TRADING OF SHARES

The accumulated deviation in the closing prices of A shares of Guangzhou Pharmaceutical Company Limited (the “Company”) for the three consecutive days, namely 17 November, 18 November and 19 November 2009, has reached 20%, which was regarded as unusual fluctuations in trading of shares under relevant regulations of the Listing Rules of The Shanghai Stock Exchange.

2. DETAILS OF RELEVANT INFORMATION CONCERNED AND VERIFIED BY THE COMPANY

- (1) After self-examination of the Company and written response from the Company’s controlling shareholder, namely Guangzhou Pharmaceutical Holdings Limited (“GPHL”), apart from the information previously disclosed by the Company, it is confirmed that both the Company and GPHL have no information which shall be discloseable and with significant impact on the Company’s share price as at the date of this announcement. The Company and GPHL decided not to pursue with any plans of major asset restructuring, acquisition and distribution of shares and other matters of significance within the next three months.
- (2) The recent operations of the Company have been normal, its internal and external operation environments have not changed significantly and the H1N1 flu has no significant impact on the Company’s overall operations.

3. STATEMENT ON WHETHER THERE WAS ANY SIGNIFICANT DISCLOSEABLE INFORMATION

The Directors of the Board (the “Board”) of the Company confirm that the Company has not been engaged in any events with significant impact on the Company’s share price, which are discloseable under relevant regulations of the Listing Rules of The Shanghai Stock Exchange, neither is the Board aware of any information with significant impact on the Company’s share price, which is discloseable under relevant regulations of the Listing Rules of The Shanghai Stock Exchange.

4. NECESSARY NOTICE OF RISKS BY THE COMPANY

The Company’s designated media for publication of its information includes Shanghai Securities News, the website of The Shanghai Stock Exchange (<http://www.sse.com.cn>) and the website of The Stock Exchange of Hong Kong Limited (<http://www.hkex.com.hk>). Investors are advised to pay attention to investment risks.

This announcement is made pursuant to Rule 13.09 (2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Board of
Guangzhou Pharmaceutical Company Limited

Guangzhou, the PRC, 19 November 2009

As at the date of this announcement, the Board comprises Mr. Yang Rongming, Mr. Shi Shaobin, Mr. Feng Zansheng as Executive Directors and Mr. Wong Hin Wing, Mr. Liu Jinxiang, Mr. Li Shanmin and Mr. Zhang Yonghua as Independent Non-executive Directors.